Deanna N Jones1, Jennifer H Jordan1, Giselle C Meléndez2, Zanetta Lamar1, Alexandra Thomas1, Dalane W Kitzman1, Cynthia Suerken3, Ralph B D'Agostino3, W Gregory Hundley4. 1. Department of Internal Medicine, Section of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 2. Department of Internal Medicine, Section of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Pathology, Section of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 3. Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 4. Department of Internal Medicine, Section of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Radiological Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Internal Medicine, Cardiology Division, Virginia Commonwealth University Health Sciences, Richmond, Virginia. Electronic address: greg.hundley@vcuhealth.org.
Abstract
OBJECTIVES: This study sought to determine the prevalence of American Heart Association/American College of Cardiology Foundation (AHA/ACCF) heart failure (HF) stages after potentially cardiotoxic chemotherapy was initiated. BACKGROUND: For individuals receiving potentially cardiotoxic chemotherapy, the frequency of transitioning from Stage A to more advanced HF stages is not well described. METHODS: In 143 Stage A HF patients with breast cancer, lymphoma and leukemia, renal cell carcinoma, or sarcoma prior to and then at 3, 6, and 12 to 24 months after potentially cardiotoxic chemotherapy was initiated, we obtained blinded cardiac magnetic resonance measurements of left ventricular ejection fraction (LVEF). RESULTS: Three months after potentially cardiotoxic chemotherapy was initiated, 18.9% of patients transitioned from Stage A to Stage B HF. A total of 83% and 80% of patients with Stage A HF at 3 months, respectively, exhibited Stage A HF at 6 and 12 to 24 months; 68% and 56% of those with Stage B HF at 3 months, respectively, exhibited Stage B HF at 6 and 12 to 24 months (p < 0.0001 and p = 0.026, respectively). CONCLUSIONS: Transitioning from Stage A to Stage B or remaining in Stage A HF 3 months after potentially cardiotoxic chemotherapy was initiated relates to longer-term (6 to 24 months post-treatment) assessments of HF stage.
OBJECTIVES: This study sought to determine the prevalence of American Heart Association/American College of Cardiology Foundation (AHA/ACCF) heart failure (HF) stages after potentially cardiotoxic chemotherapy was initiated. BACKGROUND: For individuals receiving potentially cardiotoxic chemotherapy, the frequency of transitioning from Stage A to more advanced HF stages is not well described. METHODS: In 143 Stage A HFpatients with breast cancer, lymphoma and leukemia, renal cell carcinoma, or sarcoma prior to and then at 3, 6, and 12 to 24 months after potentially cardiotoxic chemotherapy was initiated, we obtained blinded cardiac magnetic resonance measurements of left ventricular ejection fraction (LVEF). RESULTS: Three months after potentially cardiotoxic chemotherapy was initiated, 18.9% of patients transitioned from Stage A to Stage B HF. A total of 83% and 80% of patients with Stage A HF at 3 months, respectively, exhibited Stage A HF at 6 and 12 to 24 months; 68% and 56% of those with Stage B HF at 3 months, respectively, exhibited Stage B HF at 6 and 12 to 24 months (p < 0.0001 and p = 0.026, respectively). CONCLUSIONS: Transitioning from Stage A to Stage B or remaining in Stage A HF 3 months after potentially cardiotoxic chemotherapy was initiated relates to longer-term (6 to 24 months post-treatment) assessments of HF stage.
Authors: Giselle C Meléndez; Bunyapon Sukpraphrute; Ralph B D'Agostino; Jennifer H Jordan; Heidi D Klepin; Leslie Ellis; Zanetta Lamar; Sujethra Vasu; Glenn Lesser; Gregory L Burke; Kathryn E Weaver; William O Ntim; W Gregory Hundley Journal: Am J Cardiol Date: 2017-03-22 Impact factor: 2.778
Authors: Elizabeth Tan-Chiu; Greg Yothers; Edward Romond; Charles E Geyer; Michael Ewer; Deborah Keefe; Richard P Shannon; Sandra M Swain; Ann Brown; Louis Fehrenbacher; Victor G Vogel; Thomas E Seay; Priya Rastogi; Eleftherios P Mamounas; Norman Wolmark; John Bryant Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Sinziana Seicean; Andreea Seicean; Juan Carlos Plana; G Thomas Budd; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: Saro H Armenian; Christina Lacchetti; Ana Barac; Joseph Carver; Louis S Constine; Neelima Denduluri; Susan Dent; Pamela S Douglas; Jean-Bernard Durand; Michael Ewer; Carol Fabian; Melissa Hudson; Mariell Jessup; Lee W Jones; Bonnie Ky; Erica L Mayer; Javid Moslehi; Kevin Oeffinger; Katharine Ray; Kathryn Ruddy; Daniel Lenihan Journal: J Clin Oncol Date: 2016-12-05 Impact factor: 44.544
Authors: Peter Brubaker; Ashley Jensen; Jennifer Jordan; Zanetta Lamar; Shannon Mihalko; Mark Haykowsky; Lee Jones; Ralph D Agostino; Dalane Kitzman; Kerryn Reding; W Gregory Hundley Journal: JACC Cardiovasc Imaging Date: 2019-07-17
Authors: Kerryn W Reding; Nathaniel S O'Connell; Ralph B D'Agostino; William Hundley; Alexander R Lucas; Amy C Ladd; Jennifer H Jordan; Emily M Heiston; Yaorong Ge; W Gregory Hundley Journal: Cardiooncology Date: 2021-05-08
Authors: Cynthia K Suerken; Ralph B D'Agostino; Jennifer H Jordan; Giselle C Meléndez; Sujethra Vasu; Zanetta S Lamar; W Gregory Hundley Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501